# Capricor Shares HOPE-3 Data Update

> Capricor presents HOPE-3 extension results and deramiocel progress for Duchenne muscular dystrophy treatment.
- Title: Capricor Shares HOPE-3 Data Update · Seekingalpha | Shortify
- Summary: Capricor presents HOPE-3 extension results and deramiocel progress for Duchenne muscular dystrophy treatment. Capricor Therapeutics shared HOPE-3 open-label…
- Keywords: capricor, hopem3, deramiocel, duchenne muscular dystrophy, pdufa, open-label extension, money, business, Shares, HOPE-3, Data, Update
- Source: Seekingalpha — https://seekingalpha.com/article/4952622-capricor-therapeutics-inc-capr-discusses-hopeminus-3-open-label-extension-data-and-deramiocel
- Author: SA Transcripts
- Published: 2026-10-08T00:12:27+00:00
- Read time: 1 min
- Topics: capricor, hopem3, deramiocel, duchenne muscular dystrophy, pdufa, open-label extension, money, business
## Capricor Webinar Announcement
Capricor Therapeutics hosts webinar to share HOPE-3 open-label extension data and deramiocel updates for Duchenne muscular dystrophy treatment.
## Webinar Details
Webinar recorded for public access, with Q&A session planned for end of presentation.
## Company Participants
Linda Marbán, Co-Founder, President, CEO & Director leads presentation with Dr. Craig McDonald and Dr. Chet Villa.
## HOPE-3 Update
Capricor discusses HOPE-3 2-year open-label extension data and deramiocel progress for Duchenne muscular dystrophy treatment.
## PDUFA Timeline
Company shares data ahead of November PDUFA date for regulatory approval timeline.
## Key takeaway

Capricor Therapeutics shared HOPE-3 open-label extension data and deramiocel updates for Duchenne muscular dystrophy ahead of November PDUFA date.